NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristcs of human mammary tumors

Pharmacogenetics and Genomics

Volumn 19, Issue 7, 2009, Pages 505-512

  Hubackova, Miluse ^a,b   Vaclavikova, Radka ^a   Mrhalova, Marcela ^c   Kubackova, Katerina ^b   Kodet, Roman ^c   Gut, Ivan ^a   Soucek, Pavel ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Pathology and Molecular Medicine   (Canada)

Author keywords

Immunohistochemistry; NQO1; Polymorphism; Transcript

Indexed keywords

FORMALDEHYDE; PARAFFIN; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE) 1; UNCLASSIFIED DRUG; MESSENGER RNA; NQO1 PROTEIN, HUMAN; PROLINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SERINE;

ADULT; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CONTROLLED STUDY; DNA POLYMORPHISM; EVALUATION; FEMALE; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

BREAST NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, SINGLE NUCLEOTIDE; PROLINE; RNA, MESSENGER; SERINE;

EID: 67651230615     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32832cf9cf     Document Type: Article

References (24)

1. Hosoda S, Nakamura W, Hayashi K. Properties and reaction mechanism of DT-diaphorase from rat liver. J Biol Chem 1974; 249:6416-6423.
2. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y. Regulation of TP53 stability and TP53-dependent apoptosis by NADH quinone oxidoreductase-1. Proc Natl Acad Sci USA 2001; 98:1188-1193.
3. Siegel D, Ross D. Immunodetection of NAD(P)H: quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 2000; 29:246-253.
4. Siegel D, Beall H, Senekowitsch C, Kasai M, Arai H, Gibson NW, Ross D. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 1992; 31:7879-7885.
5. Walton MI, Smith PJ, Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 1991; 3:199-206.
6. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 2001; 59:263-268.
7. Sarmanova J, Susova S, Gut I, Mrhalova M, Kodet R, Adamek J, Roth Z, Soucek P. Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Genet 2004; 12:848-854.
8. Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grunewald K, Haun M, Kraft HG. Association of NQO1 polymorphism with spontaneous breast cancer it two independent populations. Br J Cancer 2004; 90:1989-1994.
9. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008; 40:844-853.
10. Tavassoeli FA, Devilee P. WHO Classification of Tumours, No.4: Pathology and Genetics, Tumours of the Breast and Female Genital Organs. Lyon: IARC; 2003. pp. 432.
11. Soucek P, Anzenbacher P, Skoumalova I, Dvorak M. Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells. Stem Cells 2005; 23:1417-1422.
12. Kai K, Nishimura R,Arima N, Miyayama H,Iwase N. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol 2006; 11:426-433.
13. Von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, et al. German Breast Group. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008; 10:R30.
14. Fowke JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT, Zheng W. Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2004; 13:1308-1315.
15. Lewis AM, Ough M, Du J, Tsao MS, Oberley LW, Cullen JJ. Targeting NAD(P)H:Quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog 2005; 43:215-224.
16. Awadallah NS, Dehn D, Shah RJ, Russell Nash S, Chen YK, Ross D, et al. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol 2008; 16:24-31.
17. Jamieson D, Wilson K, Pridgeon S, Margetts JP, Edmondson RJ, Leung HY, et al. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. Clin Cancer Res 2007; 13:1584-1590.
18. Basu S, Brown JE, Flannigan GM, Gill JH, Loadman PM, Martin SW, et al. NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C. Int J Oncol 2004; 25:921-927.
19. Cleton-Jansen AM, van Eijk R, Lombaerts M, Schmidt MK, Van't Veer LJ, Philippo K, et al. ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism. BMC Cancer 2008; 8:105.
20. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999; 9:113-121.
21. Zhang J, Schulz WA, Li Y, Wang R, Zotz R, Wen D, et al. Association of NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis 2003; 24:905-909.
22. Sarbia M, Bitzer M, Siegel D, Ross D, Schulz WA, Zotz RB, et al. Association between NAD(P)H:quinone oxidoreductase 1 (NQO1) inactivating C609 T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 2003; 107:381-386.
23. Anwar A, Dehn D, Siegel D, Kepa JK, Tang LJ, Pietenpol JA, Ross D. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem 2003; 278:10368-10373.
24. Gong X, Kole L, Iskander K, Jaiswal AW. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor TP53 against 20S proteasomal degradation leading to stabilization and activation of TP53. Cancer Res 2007; 67:5380-5388.